D. Boral Capital Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 450.46% from the company’s current price.

A number of other equities research analysts also recently issued reports on the stock. Compass Point set a $10.00 target price on Compass Therapeutics in a research note on Monday, October 6th. Citizens Jmp initiated coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Citigroup assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $5.45 on Tuesday. The business has a 50-day moving average of $4.96 and a 200-day moving average of $3.89. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $5.86. The stock has a market capitalization of $969.34 million, a price-to-earnings ratio of -12.11 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, sell-side analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in Compass Therapeutics during the first quarter worth about $34,000. Simplicity Wealth LLC increased its stake in Compass Therapeutics by 81.8% in the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock valued at $220,000 after buying an additional 38,093 shares during the last quarter. Creative Planning bought a new position in shares of Compass Therapeutics during the 2nd quarter worth approximately $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth approximately $84,000. Finally, Invesco Ltd. grew its holdings in shares of Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after acquiring an additional 21,578 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.